Harbour Investments Inc. Reduces Position in Zoetis Inc. (NYSE:ZTS)

Harbour Investments Inc. cut its position in Zoetis Inc. (NYSE:ZTS) by 7.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,414 shares of the company’s stock after selling 122 shares during the period. Harbour Investments Inc.’s holdings in Zoetis were worth $230,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of ZTS. Mission Wealth Management LP grew its holdings in shares of Zoetis by 2.0% during the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after buying an additional 59 shares in the last quarter. Hancock Whitney Corp grew its holdings in Zoetis by 0.3% in the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after purchasing an additional 61 shares during the period. VeraBank N.A. grew its holdings in Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after purchasing an additional 62 shares during the period. Procyon Advisors LLC grew its holdings in Zoetis by 1.4% in the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after purchasing an additional 63 shares during the period. Finally, Deseret Mutual Benefit Administrators grew its holdings in Zoetis by 6.6% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock valued at $170,000 after purchasing an additional 65 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,862 shares of company stock valued at $312,254. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Down 0.2 %

ZTS stock opened at $162.86 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.33. The firm’s 50-day simple moving average is $166.76 and its 200 day simple moving average is $175.52. The stock has a market cap of $72.93 billion, a PE ratio of 29.77, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.23%. Zoetis’s payout ratio is 36.56%.

Analyst Ratings Changes

Several research firms have recently issued reports on ZTS. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Finally, Barclays upped their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $215.90.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.